Researchers at the ICR co-led a recent study showing that it is possible to reverse drug resistance and slow tumour progression in prostate cancer by targeting myeloid white blood cells. Tumours can ...

Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP ...

Projects for the 2024/2025 PhD studentships are below. You will also find a link to further information about our application process, our application portal and mailing list, should you wish to be ...

Jesse was two years old when he was diagnosed with B-cell acute lymphoblastic leukaemia, a type of blood and bone marrow ...

Professor Nicholas van As is clinical lead for stereotactic body radiotherapy (SBRT) at The Royal Marsden, Co-Chair of the UK SBRT consortium and the national clinical lead for NHS England’s ...

Professor Clare Isacke aims to identify the processes by which tumour cells recruit non-cancerous cells during metastasis. She has held several senior positions at the ICR, including acting as Interim ...

The National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research is the only BRC focused ...

Professor Richard Houlston is Head of the Division of Genetics and Epidemiology. His research focuses on the identification and characterisation of genetic susceptibility to cancer. Group: Cancer ...

Scientists at The Institute of Cancer Research, London, employ a wide variety of computational approaches in order to better understand cancer and discover new treatments. This includes various ...

The ICR-CTSU is a CR-UK funded, internationally recognised methodologist led clinical trials unit, providing cancer-focussed clinical trial research expertise. We lead pioneering, efficient, ...

Professor Robin Jones is Group Leader in Sarcoma Clinical Trials at The Institute of Cancer Research and Consultant Medical Oncologist at The Royal Marsden. He is a specialist in the treatment of bone ...

Professor Banerji's group focuses on the development and validation of quantifiable and reproducible robust pharmacodynamic biomarkers in normal and tumour tissue that can be used in first-in-human ...